AURA · Aura Biosciences, Inc.
$7.80
+0.03 (+0.39%)
At close · Aug 21
Market Cap
$805.79M
Shares
103.70M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.80
Open$7.77
Day$7.65–8.09
52W close$4.97–8.90
Avg vol 30d627K
Short int6.4M · 6.1% float · 18.5d
Short vol49%
Last earningsMay 27, 2026
DataOct 2021–Aug 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Sep 18, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+20%
above
Price vs 50-day avg
+9%
above
RSI (14)
57
neutral
MACD trend
Positive
52-week position
72%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+11%
trailing
6-month return
+27%
trailing
YTD return
+43%
this year
Relative strength
+15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+16% holders QoQ · +37 funds added
Insider flow
Distributing
Net -$82.3K over 90 days · 100% sells
Short interest
Rising
6.13% of float · ▲ +13.4% MoM · 18.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
147 holders — near 3-yr high, broad support
Squeeze score
92
high risk · 0–100
Fundamentals
EPS growth
−1%
Y/Y
Free cash flow
$-85.2M
Balance sheet
$59.5M
net cash
Quant / Vol
risk profile
Volatility
57%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
5.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 11, 2026
Restructuring costs (cash payments and costs related to the Real
· third quarter of 2026
$2.9M – $3.2M
Restructuring charges
· third quarter of 2026
Initiated
$2.9M – $3.2M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+20%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
72%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+16% holders QoQ · +37 funds added
Insider flow
Distributing
Net -$82.3K over 90 days · 100% sells
Short interest
Rising
6.13% of float · ▲ +13.4% MoM · 18.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
147 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $8 · 72%
Range high $9
vs 200-day avg +20%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Phase 3 CoMpass trial enrollment | 108 | the second quarter ended June 30, 2026 | — |
| workforce reduction | 20% | the second quarter ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AURA
this stock
Aura Biosciences, Inc.
|
$805.79M | +43.1% | — | — | 6.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +20.9% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AURA | +1.4% | +10.6% | +27.0% | +11.3% | +43.1% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +2.8% | +7.0% | +15.5% | +8.8% | +30.8% |
Key facts
CIK
1501796
CUSIP
05153U107
13F (30d)
140 filings
138 filers
Visit website
Investor relations